| Hei-Jen Jou,Tzong-An Wang,Chun-Sen Hsu,Wen-Huey Wu |
------>authors3_c=None ------>paper_class1=1 ------>Impact_Factor=None ------>paper_class3=1 ------>paper_class2=1 ------>vol=27 ------>confirm_bywho=tzengcr ------>insert_bywho=morri ------>Jurnal_Rank=None ------>authors4_c=None ------>comm_author= ------>patent_EDate=None ------>authors5_c=None ------>publish_day=None ------>paper_class2Letter=None ------>page2=66 ------>medlineContent= ------>unit=E0111 ------>insert_date=20020806 ------>iam=3 ------>update_date= ------>author=??? ------>change_event=5 ------>ISSN=None ------>authors_c=None ------>score=-64 ------>journal_name=Nutritional Sciences Journal ------>paper_name=Health Benefits of Phytoestrogens in Premenopausal Women ------>confirm_date=20060201 ------>tch_id=067013 ------>pmid=19131846 ------>page1=56 ------>fullAbstract=OBJECTIVES: Equol, a metabolite of the isoflavone daidzein, is hypothesized to play a major role in the health benefits of soy. We examined the effect of a new S-equol supplement on menopausal symptoms and mood states. DESIGN: We conducted a randomized, double-blind, placebo-controlled trial with our new equol supplement for 12 weeks with 134 Japanese women (aged 40-59 years). They were randomly assigned to three groups: placebo (n = 44), 10 mg of equol per day (EQ-1; n = 44), and 10 mg of equol three times per day (EQ-3; n = 46). Habitual isoflavone intake was limited to 20 mg/d. Participants completed menopausal symptom and Profile of Mood States questionnaires at baseline and postintervention. Physical examination and blood and 24-hour urine collection were performed at baseline and postintervention. RESULTS: At baseline, total menopausal symptom score varied by menopausal and equol producer status (34.3% producers). A total of 127 participants (94.8%) completed the trial. No adverse effects were reported, except for a systemic rash in one EQ-3 woman. The anxiety scores of equol producers were lower than those of nonproducers (P < 0.05). Significant differences between premenopausal and perimenopausal/postmenopausal symptom scores were observed for anxiety, somatic, and total scores. After the EQ-3 intervention, perimenopausal/postmenopausal equol nonproducers showed significant decreases from baseline in all menopausal symptom scores except depression (P < 0.01). Compared with placebo, the EQ-3 group showed significant decreases in depression scores (P < 0.05), as well as significant decreases in Tension-Anxiety (P < 0.05), Depression-Dejection (P < 0.05) and Fatigue (P < 0.01) and increases in Vigor (P < 0.05) of the Profile of Mood States. CONCLUSION: S-equol supplement improved mood-related symptoms in perimenopausal/postmenopausal equol nonproducers. ------>tmu_sno=None ------>sno=5776 ------>authors2=None ------>authors3=None ------>authors4=None ------>authors5=None ------>authors6=None ------>authors6_c=None ------>authors=Hei-Jen Jou,Tzong-An Wang,Chun-Sen Hsu,Wen-Huey Wu ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c=None ------>publish_area=None ------>updateTitle=New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. ------>language=1 ------>check_flag= ------>submit_date= ------>country=None ------>no=2 ------>patent_SDate=None ------>update_bywho= ------>publish_year=2002 ------>submit_flag= ------>publish_month=None |